Patents by Inventor Benito Munoz

Benito Munoz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA
    Publication number: 20200399276
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
    Type: Application
    Filed: June 29, 2020
    Publication date: December 24, 2020
    Applicant: THE BROAD INSTITUTE, INC.
    Inventors: EAMON COMER, NOBUTAKA KATO, CHRISTINA SCHERER, JESSICA BASTIEN, JEREMY DUVALL, TIMOTHY LEWIS, MORGANE SAYES, MATTHEW LEIGHTY, JUN PU, JENNIFER BEAUDOIN, BERTRAND BRAIBANT, BENITO MUNOZ
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    Publication number: 20200385365
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: December 17, 2019
    Publication date: December 10, 2020
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY
    Publication number: 20200360348
    Abstract: The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
    Type: Application
    Filed: December 11, 2019
    Publication date: November 19, 2020
    Inventors: Benito Munoz, Cecilia M. Bastos, John Miller
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20200308198
    Abstract: The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Inventors: Matthew Cullen, Sheila Hauck, Bolin Geng, Megan Foley, Cecilia M. Bastos, Benito Munoz, Markus Haeberlein, Bradley Tait
  • Compounds and methods for the treatment of malaria
    Patent number: 10738055
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 11, 2020
    Assignee: The Broad Institute, Inc.
    Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10738040
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: August 11, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    Patent number: 10738011
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IVa), (Va), (IV), or (V) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 11, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20200190072
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Application
    Filed: July 12, 2019
    Publication date: June 18, 2020
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 10662207
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 26, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS
    Publication number: 20200140425
    Abstract: Disclosed are compounds that can be used for treating tuberculosis.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 7, 2020
    Inventors: Timothy A. Lewis, Sivaraman Dandapani, Deborah Hung, Benito Munoz, Partha Nag, Sarah Grant, Tomohiko Kawate
  • KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200061050
    Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychriatic disorders, metabolic disorders, and cancer.
    Type: Application
    Filed: November 21, 2018
    Publication date: February 27, 2020
    Inventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
  • 4-SULFONYLAMINOCARBONYLQUINOLINE DERIVATIVES FOR INCREASING CFTR ACTIVITY
    Publication number: 20200055844
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: April 30, 2018
    Publication date: February 20, 2020
    Inventors: Daniel PARKS, Benito MUNOZ
  • Compounds, compositions, and methods for modulating CFTR
    Patent number: 10550106
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 4, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, Daniel Parks, David Kombo
  • Compounds, compositions, and methods of increasing CFTR activity
    Patent number: 10548878
    Abstract: The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: February 4, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Cecilia M. Bastos, John Miller
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20200010461
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Application
    Filed: June 21, 2017
    Publication date: January 9, 2020
    Inventors: Daniel Parks, Cecilia M. Bastos, Matthew Cullen, Benito Munoz
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20190308960
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Application
    Filed: November 14, 2018
    Publication date: October 10, 2019
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 10392372
    Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 27, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
    Patent number: 10392378
    Abstract: The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IIIa), (III), or (IV) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 27, 2019
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS
    Publication number: 20190256474
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: October 26, 2017
    Publication date: August 22, 2019
    Inventors: Daniel Parks, Benito Munoz
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20190248765
    Abstract: The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Application
    Filed: October 26, 2017
    Publication date: August 15, 2019
    Inventors: Daniel Parks, Benito Munoz